Lynn Seely - 10 Feb 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
President and CEO, Director
Signature
/s/ Matthew Lang, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
10 Feb 2025
Net transactions value
$0
Form type
4
Filing time
26 Feb 2025, 19:33:46 UTC
Previous filing
14 Jun 2024
Next filing
18 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +337,500 +169% $0.000000 537,500 10 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +1,350,000 $0.000000 1,350,000 10 Feb 2025 Common Stock 1,350,000 $0.5535 Direct F2
transaction LYEL Option (right to buy) Award $0 +168,750 $0.000000 168,750 10 Feb 2025 Common Stock 168,750 $0.5535 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
F2 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
F3 The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.